Prostate cancer (PCa) contains a small population of cancer stem cells (CSCs) that contribute to its initiation and progression. The development of specific markers for identification of the CSCs may lead to new diagnostic strategies of PCa. Increased aldehyde dehydrogenase 1A1 (ALDH1A1) activity has been found in the stem cell populations of leukemia and some solid tumors. The aim of the study was to investigate the stem-cell-related function and clinical significance of the ALDH1A1 in human PCa. ALDEFLUOR assay was used to isolate ALDH1A1 þ cells from PCa cell lines. Stem cell characteristics of the ALDH1A1 þ cells were then investigated by in vitro and in vivo approaches. The ALDH1A1 expression was also analyzed by immunohistochemistry in 18 normal prostate and 163 PCa tissues. The ALDH1A1
Prostate cancer (PCa) contains a small population of cancer stem cells (CSCs) that contribute to its initiation and progression. The development of specific markers for identification of the CSCs may lead to new diagnostic strategies of PCa. Increased aldehyde dehydrogenase 1A1 (ALDH1A1) activity has been found in the stem cell populations of leukemia and some solid tumors. The aim of the study was to investigate the stem-cell-related function and clinical significance of the ALDH1A1 in human PCa. ALDEFLUOR assay was used to isolate ALDH1A1 þ cells from PCa cell lines. Stem cell characteristics of the ALDH1A1 þ cells were then investigated by in vitro and in vivo approaches. The ALDH1A1 expression was also analyzed by immunohistochemistry in 18 normal prostate and 163 PCa tissues. The ALDH1A1
þ PCa cells showed high clonogenic and tumorigenic capacities, and serially reinitiated transplantable tumors that resembled histopathologic characteristics and heterogeneity of the parental PCa cells in mice. Immunohistochemical analysis of human prostate tissues showed that ALDH1A1 þ cells were sparse and limited to the basal component in normal prostates. However, in tumor specimens, increased ALDH1A1 immunopositivity was found not only in secretory type cancer epithelial cells but also in neuroendocrine tumor populations. Furthermore, the high ALDH1A1 expression in PCa was positively correlated with Gleason score (P ¼ 0.01) and pathologic stage (P ¼ 0.01), and inversely associated with overall survival and cancer-specific survival of the patients (P ¼ 0.00093 and 0.00017, respectively). ALDH1A1 could be a prostate CSC-related marker. Measuring its expression might provide a potential approach to study tumorigenesis of PCa and predict outcome of the disease. KEYWORDS: ALDH1A1; biomarkers; cancer stem cell; prostate cancer; prognosis Prostate cancer (PCa) is the most frequently diagnosed tumor and the second largest cancer contributing to mortality in men. Its treatment depend on the stage of the disease, resulting in variable clinical outcomes. 1 Prognostic markers that can identify aggressive PCa and help select appropriate therapy to finally reduce the mortality are therefore urgently needed. However, current techniques are not accurate enough to predict the outcome of PCa. New diagnostic modalities have to be developed. 1 The cancer stem cell (CSC) model proposes that tumorigenesis is driven by CSCs that might be derived from mutated adult stem cells (SCs). CSCs are functionally defined by the following criteria: high tumorigenicity, self-renewal capacity, and recapitulating the heterogeneity of the original primary tumor. 2 Although being present in small numbers in tumor tissues, CSCs are believed to be responsible for progression and relapse of cancer. 3 Therefore, CSCs could provide a prognostic strategy for human malignancies. For example, CD133, a commonly used marker to characterize colon CSCs, was proven to be an independent prognostic factor that correlated with low survival of colon cancer patients. 4 Accumulating evidence posit that CSC concept is also relevant to PCa. 5 The growth and metastasis of PCa might be promoted by CSCs that are responsible for its aggressiveness and frequently recur after therapy. 6 Therefore, identification of specific markers for the CSCs would enhance our understanding of the tumor biology of prostate. More importantly, these specific markers could be developed as a new diagnostic system for monitoring the progression of PCa and offering the best opportunity to prevent its recurrence, and hence probably cure the challenging malignancy.
Human mature prostatic glands consist of basal, secretory luminal, and neuroendocrine cells. Prostate CSs are suggested to localize in the basal cell layer. Several candidate populations of prostate stem/progenitors cells have been reported, including those expressing cell surface markers, CD44, a2b1, or CD133. 7, 8 For example, Collins et al 7 found that the a2b1 þ cells comprised B15% of CD44 þ basal cells and possessed high colony-forming efficiency and an ability to generate prostate-like acini when engrafted in nude mice. 7 As CSCs share properties with normal SCs, CSCs of PCa have been isolated using these cell surface markers. 5 However, PCa cells that highly express the markers do not always appear to tightly mark a cell population with the CSC characteristics. 5 In particular, the ability of these cells to successively reinitiate transplantable tumors remains uncertain, while serial xenotransplantation is regarded as the gold standard for proving the existence of CSCs. 9, 10 Moreover, clinical significance of the surface markers, especially relevance for PCa patients' outcome is not clear.
Aldehyde dehydrogenase (ALDH) is an enzyme involved in intracellular retinoic acid production.
11 ALDH1A is an important member of the ALDH family that includes 17 genes encoding different substrate specificities, of which ALDH1A1 catalyzes the oxidation of retinal to retinoic acid. 11 Retinoic acid signaling is linked to cellular differentiation during development and has important function in SC self-protection throughout an organism's lifespan. [12] [13] [14] [15] Activation of ALDH1A1 has been found in the SC populations of multiple myeloma and acute myeloid leukemia. 16 Ginestier et al 17 showed that ALDH1A1 was a marker of normal and malignant human mammary SCs and a predictor of poor clinical outcome of breast cancer patients. We recently showed that the ALDH1A1 þ lung cancer cells could generate tumors that resembled the heterogeneity of the parental cancer cells. 18 Furthermore, elevated ALDH1A1 expression was correlated with the stage and grade of lung tumors and associated with a poor prognosis for the lung cancer patients. 18 In addition, high ALDH activity was recently proven to be a novel functional marker of murine prostate SCs. 19 However, no research has been reported regarding the role of ALDH1A1 in tumorigenesis of human prostate and its clinical importance in the disease.
In this study, we first used ALDEFLUOR assay and fluorescence-activated cell sorting (FACS) to isolate ALDH1A1 þ cells from human PCa cell lines. The ALDH1A1 þ cancer cells showed important CSC properties: high in vitro tumorigenicity, in vivo tumor initiation and self-renewal capacities, and successively reinitiating transplantable tumors that gave rise to a heterogeneous population of cancer cells. Moreover, immunohistochemistry analysis of clinical specimens showed that ALDH1A1 þ cells were sparse and resided in the basal layers of normal prostate glands. However, in cancer specimens, ALDH1A1 immunopositivity was found not only within secretory type cancer epithelia but also among neuroendocrine tumor cells. High ALDH1A1 expression correlated significantly with the patient's poor survival. ALDH1A1 could therefore be a prostate CSC-associated marker, and might provide a potential prognostic factor for the malignant progression of PCa.
MATERIALS AND METHODS Cell Lines and Cultures
PCa cell lines, PC3 cells, and LNCaP cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in the culture medium recommended by ATCC and harvested when they were in the logarithmic phase of growth for use in the following experiments.
Isolation of ALDH1A1
þ Cell Population by ALDEFLUOR Assay and FACS An ALDEFLUOR kit (StemCell Technologies, Durham, NC, USA) optimized for interaction with human ALDH1A1 was used to identify ALDH1A1 þ cells as previously described. 18 Briefly, the brightly fluorescent ALDH1A1-expressing cells were detected using an Aria cell sorter (BD Biosciences, San Jose, CA, USA). Side-scatter and forward-scatter profiles were used to reduce cell doublets. Nonviable cells were eliminated using the viability dye 4 0 ,6-diamidino-2-phenylindole (Sigma, St Louis, MO, USA). Specific ALDH1A1 activity was based on the difference between the presence/ absence of the ALDEFLUOR inhibitor diethylaminobenzaldehyde (DEAB) (Sigma). Data were analyzed using Cell Quest software (BD Biosciences). Each experiment was repeated three times.
Clonal Analysis and Clonogenic Assays
Cells were plated at a density of 200 per well in a six-well tissue culture dish, as described in our previous report. 18 Clones with 450 cells were scored at the end of week 2. The percentage of cells that initiated a clone was presented as cloning efficiency. For clonogenic assays, cells were plated at 1000 per well in six-well culture dishes coated with a thin layer of 1% solidified agar. 9, 18 The appearance of spheres within 3 weeks was considered as clonogenicity. For each cell type, triplicate samples were performed and clones or spheres were counted in a blind manner by two individuals.
Xenografting
Cells were resuspended in serum replacement medium at 1000 cells per 50 ml and mixed with an equal volume of Matrigel (BD Biosciences). The cells were then implanted into the dorsal prostate of 10 NOD/SCID mice, which has been widely used as an 'orthotopic' implantation site for human PCa. 9 Tumorigenicity was measured mainly by tumor incidence (ie, the number of tumors/the number of injections), size of tumor, and latency (ie, time from injection to detection of palpable tumors). The mice were observed for 6 weeks to allow tumor growth and then killed under deep anesthesia with pentobarbital (Sigma 18 Serial transplantations of the PCa xenografts were performed by regrafting the freshly disassociated cells into male mice. The disassociated cells were also reanalyzed by using ALDEFLUOR assay for FACS analysis, as described above. Immunofluorescence study was undertaken on the cells from the engrafted tumors to evaluate expressions of ALDH1A1, CD44, and androgen receptor (AR) as described below. Moreover, a portion of each tumor tissue was fixed in 10% formaldehyde and embedded in paraffin for histopathologic study.
Immunohistochemical and Immunofluorescence Analyses
To explore expression patterns of ALDH1A1 in normal prostate and PCa tissues and their relationship with those of CD44, AR, and chromogranin A, we obtained tissue microarrays (TMAs) (US Biomax, Frederick, MD, USA) constructed from 18 normal prostate and 64 PCa tissues (Table 1) . Immunohistochemical (IHC) staining was carried out on the consecutive TMA sections using antibodies against ALDH1A1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD44 (eBioscience, San Diego, CA, USA), AR (Santa Cruz Biotechnology), and chromogranin A (Vector Laboratories, Burlingame, CA, USA), as previously described. 20, 21 Immunoreactive staining intensity for each antibody was rated according to the following scale: no visible staining ¼ 0, faint staining ¼ 1, moderate staining ¼ 2, and strong staining ¼ 3. The total number of cells with positive staining for the antibodies was quantitated on each tissue spot (0.6 mm 2 ) of the TMAs. The percentage of cells with positive staining was graded as 0, o10, 10-25, 25-50, and X50-75%.
As the clinical follow-up information for the specimens on the TMAs was not available to evaluate the associations between ALDH1A1 expression and PCa patients' outcomes, we obtained formalin-fixed and paraffin-embedded PCa tissue sections with follow-up outcomes from the School of Clinical Medicine of Southeast University in China. The specimens were collected from 99 PCa patients who underwent radical retropubic prostatectomy between 1991 and 2003. The patients also received androgen deprivation therapy. As radiation therapy was unavailable for many patients, analysis influence of radiation on the patients was not included in the study. The minimum available follow-up on all patients was 6.72 (0.6-16.4) years. Overall survival was measured using the dates of death from any cause. Cancer-specific survival was calculated using the dates of death from PCa. The study was conducted under a protocol approved by the institutional review board for human subjects' research. Geographic characteristics of the patients, including age, histopathologic diagnosis, and the survivals, are shown in Table 2 . IHC with ALDH1A1 antibody was carried out and staining intensity was rated as described above. The total number of cells with positive staining for the antibodies was quantitated in 20 fields in each paraffin tissue section.
To elucidate whether ALDH1A1 þ PCa cells could generate engrafted tumors with heterogeneity in mice, we also examined expressions of ALDH1A1, CD44, and AR using immunofluorescence assay with the above primary antibodies on the disassociated cells from the xenografts. The cells were then stained with a fluorescently conjugated IgG (Abcam, Cambridge, MA, USA) and examined under a Leica microscope (Leica Microsystems, Buffalo, NY, USA), as previously described. 18 Each batch of slides contained a positive control and a negative control.
Statistical analysis
The statistical software SPSS12.0 (SPSS, Chicago, IL, USA) was used to analyze the differences between ALDH1A1 þ and ALDH1A1 À cells with unpaired or paired t-tests for statistical significance. Kaplan-Meier models were applied to generate life tables. Differences between groups were examined using the log-rank test. Univariate and multivariate Cox regression analyses were carried out using stepwise methods for the analysis of ALDH1A1 staining results, age, histopathologic A specimen with more than 10% overall score of ALDH1A1 was defined as one with high ALDH1A1 expression. c All P-values were determined by two-sided tests. P-values r0.05 were considered statistically significant.
parameters, and the survivals. Owing to the long follow-up period for this patient set, PSA value was unavailable for many patients. Therefore, the analysis of correlation of ALDH1A1 expression with PSA level was not included in the study.
RESULTS

Identification of a Small ALDH1A1 þ Subpopulation in PCa Cell Lines with Increased Properties of Clonogenicity
We used the ALDEFLUOR assay followed by FACS analysis to assess the presence and size of the cell population with ALDH1A1 þ expression in two human PCa cell lines. The PC3 and LNCaP cell lines had a small size of the ALDH1A1 þ population, with 2.1% (2.06 ± 1.27) and 2.0% (1.99 ± 1.18), respectively ( Figure 1a ). However, with DEAB, an ALDEFLUOR inhibitor, cells showed o0.03% ALDH1A1 þ population. ALDH1A1 þ PC3 and ALDH1A1 þ LNCaP cells showed significantly a higher colony-forming efficiency (Figure 1b) by forming larger and more clones compared with ALDH1A1 À PC3 and ALDH1A1 À LNCaP cells at the end of the clonal assays. These data indicated that ALDH1A1
þ PCa cells could possess high proliferative capacity. As anchorageindependent growth is an approximation of tumorigenesis, and CSCs are believed to be the tumor-initiating cells, 2 we further tested the ability of ALDH1A1 þ and ALDH1A1 À PCa cells to produce colonies by using soft agar assay. þ cells could be regenerated for six cycles until we prepared the paper. Histopathologic examination showed a highly cellular mass with the characteristics of PCa in engrafts from ALDH1A1
þ PCa cancer cells (Figure 2b) . The observation provides functional (Figure 2c) . Furthermore, immunofluorescence analysis showed that the disaggregated cells of engrafted tumors from ALDH1A1 þ LNCaP cells that were initially negative for CD44 and positive for AR displayed 37% (36 ± 1.3%) CD44 þ cells and 56% (56 ± 2.2%) AR À cells, respectively ( Figure 3 ). In addition, the engraftments from the ALDH1A1 þ PC3 population that was originally positive for CD44 and negative for AR showed 29% (28±1.2%) CD44 Altogether, our in vivo data suggest that ALDH1A1 þ PCa cells possess unique features of cancer stem-like cells, including initiation of tumorigenesis, self-renewal, and reinitiating serially transplantable tumors with multipotent differentiation potential.
ALDH1A1 Expression was Sparse and Limited to the Basal Component in Normal Prostates
As shown in Figure 4a , only a few ALDH1A1 þ cells, which displayed positive cytoplasmic staining, resided in the basal cell layers of normal prostate tissues. In the adjacent sections from the same normal prostate tissues, CD44 þ cells also existed in the basal component, indicating that ALDH1A1 þ and CD44
þ cells were at the same locations in prostate glands (Figure 4a ). However, comparison of ALDH1A1 and CD44 staining on the consecutive tissue sections showed that ALDH1A1 þ cells accounted for a portion of ALDH1A1 þ population, and the percentage of ALDH1A1 þ cells was statistically lower compared with that of CD44 þ cells in the same basal cell layers (Figure 4b) 
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ALDH1A1 Expression Existed in PCa Tumors with
Heterogeneous Phenotypes ALDH1A1 expression was found in tumor tissues as illustrated by strong cytoplasm staining. Furthermore, in contrast to rare ALDH1A1 þ cells in the normal basal component, a higher percentage of the ALDH1A1 þ population was found in tumor tissues (Po0.0001). In addition, IHC analysis of serial tumor sections showed that ALDH1A1 þ cells existed not only within secretory type cancer epithelial cells that showed strong AR immunopositivity (Figure 5a ) but also among neuroendocrine tumor cells that had positive chromogranin A (Figure 5b) . Although the ALDH1A1 þ cells only account for a subset of the AR þ or chromogranin A þ cancer cell populations, the observation suggests that ALDH1A1 highly expresses in a form of heterogeneity in tumor tissues, being consistent with the CSC concept, in which CSCs have a multipotent differentiation feature.
Elevated ALDH1A1 Expression is Associated with a Poor Prognosis for Patients with PCa
To assess the potential use of ALDH1A1 as a prognostic marker in PCa patients, an overall score of ALDH1A1 expression in the tissue specimens was assigned by multiplying the intensity score by the mean percentage of cells staining. ALDH1A1 expression was then stratified at three levels: absent (a specimen without any expression of ALDH1A1), present (a specimen that had o10% of cells for ALDH1A1 expression with faint staining), and a high level (a specimen with more than 10% overall score) of ALDH1A1 expression. All normal prostate tissues had r10% of cells for ALDH1A1 expression with faint staining. Therefore, 410% overall score was used as a cut-off, that is, a tumor specimen with more than 10% overall score was defined as one with high ALD-H1A1 expression. 
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On applying this criterion, high ALDH1A1 expression was found in 13 of 64 (20%) PCa tumors on TMAs (Table 1) , which were associated with high Gleason score (P ¼ 0.01) and high pathologic stage (P ¼ 0.01). Similarly, of 99 PCa tumors with clinical follow-up information, 19 (19%) tissues showed high ALDH1A1 expression (Table 2) . In 99 cancers, high ALDH1A1 expression was associated with high Gleason score (P ¼ 0.02) and high pathologic stage (P ¼ 0.02) of the tumors. However, there was no significant association between ALDH1A1 expression and patient's age (Tables 1  and 2 ). These data from two independent PCa patient populations show that high ALDH1A1 expression is correlated with aggressive behavior of prostate tumorigenesis.
Kaplan-Meier survival curve analyses of 99 PCa tumors with clinical follow-up information showed that patients with high ALDH1A1 expression in their tumors had a significantly reduced overall survival rate compared with patients who had low ALDH1A1 expression (P ¼ 0.0093) (Figure 5c ). The difference was more prominent in the PCa-specific survival data (P ¼ 0.0017). Furthermore, univariate analysis showed that high ALDH1A1 expression in PCa tumors was significantly related to overall and cancer-specific survivals with hazard ratios of 1.79 (95% CI: 1.226-2.632, P ¼ 0.0027) and 1.07 (95% CI: 1.032-1.154, P ¼ 0.0019), respectively.
Parameters, including age, high ALDH1A1 expression, Gleason score (r7 versus 48), pathologic stage (ZpT 3 vs pT 2 ), were included for the Cox regression multivariate analysis. Overall and cancer-specific survivals were used as end points. High ALDH1A1 expression consistently showed a strong and independent prognostic effect on overall and cancer-specific survivals with hazard ratios of 1.73 (95% CI: 1.163-2.527, P ¼ 0.0066) and 1.05 (95% CI: 1.028-1.107, P ¼ 0.0062), respectively. Furthermore, Gleason score of tumors was significantly associated with the overall and cancer-specific survivals with hazard ratios of 1.34 (95% CI: 1.010-2.193, P ¼ 0.0016) and 1.11 (95% CI: 1.021-2.215, P ¼ 0.0012). Pathologic stage was also significantly related to the overall and cancer-specific survivals with hazard ratios of 2.23 (95% CI: 1.713-2.899, P ¼ 0.0029) and 2.10 (95% CI: 1.771-2.736, P ¼ 0.0032). However, only age was shown as an independent prognostic factor for overall survival of the patients with hazard ratios of 1.62 (95% CI: 1.052-2.632, P ¼ 0.0458).
DISCUSSION
The development of specific markers to isolate and characterize CSCs of prostate tumors would greatly advance our understanding of tumor biology of prostate. A Hoechst 33342 efflux assay for collecting side population that preferentially expresses drug-efflux pumps has been used to enrich CSCs of leukemia and some solid tumors. 2, 3 However, the approach failed to detect a reliable side population in several commonly cultured human PCa cell lines. 9, 10 Recently, cell surface markers have been used to isolate CSCs from human PCa cells. For instance, CD44 þ /a2b1 þ PCa cells showed high colony-forming efficiency and capacity to differentiate into several cell types of prostate carcinoma. 9, 10 However, the ability of these cells to serially reinitiate transplantable tumors has not been well documented. 10 Furthermore, the reliability of using the markers to identify CSCs remains controversial. 5, 10 For example, Collins and coworkers 5 showed that a subpopulation of CD44 þ /a2b1high/ CD133 þ cells in clinical PCa specimens had SC characteristics in vitro. However, Pfeiffer and Schalken 23 recently used CD133 to isolate CSCs from PCa cell lines. Only one (DU145) of six PCa cell lines (DU145, DuCaP, LAPC-4, 22Rv1, LNCaP, and PC-3) had a detectable CD133 þ population (0.01%). There was no difference in the ability of the CD133 þ , CD133 À , and unselected DU145 cells to form colonies. In addition, although a2b1 þ PCa cells showed higher proliferative and clonogenic potentials in vitro compared with the isogenic a2b1 À PCa cells, a2b1 þ PCa cells were no more tumorigenic than the corresponding a2b1 À cells in vivo. 9 Moreover, several other cell populations have been identified that share the same marker phenotype, including circulating fibrocytes, [22] [23] [24] [25] [26] thus limiting their application in enriching CSCs from clinical specimens. 24 In this study, we successfully isolated ALDH1A1 þ cells from PCa cell lines using ALDEFLUOR assay. Several pieces of evidence support that ALDH1A1
þ PCa cells could be enriched in CSCs or stem-like cancer cells. First, the in vitro Previous studies strongly suggested that the basal cell layer of adult human prostate contained SCs. 5, 10 For example, more than 70% of proliferating cells and molecules that are important in maintaining fundamental properties of SCs localized in this basal compartment. 10, 27 Furthermore, o5% dissociated basal layer cells from adult human prostate possessed extensive proliferative capacity. 27, 28 In addition, under suitable culture conditions, a small population of prostatic basal cells maintained some developmental plasticity, in which cells transdifferentiated into neuronal/glial cells. 29 Finally, CD44 was expressed on most basal cells and purified CD44 þ prostate epithelial cells, when co-cultured with stromal cells, produced increased amounts of PSA, probably due to the differentiation of CD44 þ cells into luminal cells. 10, 30 CD44 þ cells were therefore believed to contain normal prostate SCs, and CD44 was considered as a marker for SCs in prostate epithelia. 5, 10 In this study, we show that a small ALDH1A1 þ cell population is restricted to the CD44 There are few markers clinically available for accurate prediction of the prognosis of PCa patients besides PSA and Gleason sum. 32 Owing to the heterogeneous nature of PCa, it has become clear that a combination of accurate prognostic indicators is needed to improve the ability for identifying aggressive disease, so that more individualized treatments could be offered. We here show that high ALDH1A1 expression occurs in PCa samples, and is significantly associated with the Gleason score and pathologic stage. More importantly, ALDH1 expression inversely correlates with survival of the patient with PCa. A limitation of the study is that a small sample size. If the ALDH1A1 expression could be proved as a prognostic biomarker in a future large PCa population with comprehensive clinical information, the assay for analysis of ALDH1A1 might be added to the currently available prognostic factors for improving the accuracy of outcome predictions of PCa.
In summary, using in vitro and in vivo experimental systems, we show that ALDH1A1 þ cancer cells are endowed with extensive proliferation and self-renewal potential, being able to generate tumors that might resemble the histopathologic characteristics and heterogeneity of the parental PCa cells, and therefore might have the properties of CSCs. However, further molecular biological analysis of ALDH1A1 in carcinogenesis of prostate and validating its prognostic value in a large population of PCa will be warranted.
